BioSpace News Archive

Vivera Pharmaceuticals, Inc. a California based pharmaceutical company, is proud to do its part in delivering effective testing for the detection of the COVID-19 causing CoV-2 virus.

Foundation Medicine, Inc. announced that the US FDA approved FoundationOne®CDx as the registrational companion diagnostic for Incyte’s Pemazyre™, a selective fibroblast growth factor receptor inhibitor approved for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley , to its Board of Directors. The Company also announced the resignation of current board member, Mr. Anthony Hayes .

Biotech manufacturer recommended for continued certification to ISO 9001:2015 and ISO 13485:2016

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that it has promoted John Davis Jr., M.D., M.P.H., M.S. to Head of Research and Development and Chief Medical Officer. “As Magenta continues its strong track record of progress in both Research and Development, we are further positi

New patient registry is also now available to all hospitals willing to capture meaningful data about their COVID-19 patients

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has engaged Complete Phytochemical Solutions, LLC., an internationally-recognized company specializing in unique and complex analyses and formulation development of phytochemicals, to advance the Company’s research and development initia

Expansion Helps Patients Avoid Crowds, Wait Times and Exposure in the ER or Urgent Care, While Also Providing Immediate Care with Orthopaedic Specialists

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will oversee commercial strategic planning, alliance management and corporate and business development. Mr. McClung’s appointment is the latest in the evolution of Sangamo’s leadership implemented over the last three years as t

GC Pharma, a South Korean biopharmaceutical company, participate in campaign to celebrate World Hemophilia Day.